Literature DB >> 26402453

Release of growth-differentiation factor 15 and associations with cardiac function in adult patients with congenital heart disease.

J A Eindhoven1, A E van den Bosch1, R M Oemrawsingh1, V J Baggen1, I Kardys1, J A Cuypers1, M Witsenburg1, R H van Schaik2, J W Roos-Hesselink3, E Boersma1.   

Abstract

BACKGROUND: Growth-differentiation factor-15 (GDF-15), a cytokine with broad cardiac and non-cardiac activity, has diagnostic and prognostic value in various diseases, including heart failure. We aimed to investigate the release of GDF-15 in adults with congenital heart disease (ConHD), and assess the association with cardiac function and functional capacity.
METHODS: A total of 587 consecutive adults with ConHD (median age 33 [IQR 25-41] years, 59% men, and 90% NYHA I) underwent electrocardiography, echocardiography, venepuncture and were seen by a cardiologist. A subset of 143 patients underwent bicycle ergometry on the same day.
RESULTS: Median plasma GDF-15 was 618 [IQR 487-867] ng/L. In 87 patients (15%), GDF-15 was above the reference value of normal (1109 ng/L). GDF-15 levels were higher in older patients (r=0.367, p<0.001). GDF-15 was higher in patients with elevated pulmonary pressure (median 1114 [IQR 796-2320 ng/L) than in patients with normal pulmonary pressure (median 606 [IQR 481-826] ng/L, p<0.001). GDF-15 correlated positively with NT-proBNP (r=0.445, p<0.001). In multivariate analysis adjusting for age, sex, and NT-proBNP, hs-TnT and hs-CRP, GDF-15 above the reference value was associated with NYHA class (odds ratio for NYHA≥II: 3.5 [95% CI 1.8-6.8], p<0.001), and decreased exercise capacity (odds ratio for workload >85%:0.2 [95% CI 0.06-0.8], p=0.018), but not with systolic ventricular function or ECG rhythm.
CONCLUSIONS: GDF-15 is elevated in a substantial number of patients and higher in those with elevated pulmonary pressures, regardless of underlying congenital diagnosis. GDF-15 is associated with NYHA class, NT-proBNP and exercise capacity, suggesting the marker has diagnostic and potential prognostic value in adults with ConHD.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Adult congenital heart disease; Echocardiography; Growth differentiation factor 15; Ventricular function

Mesh:

Substances:

Year:  2015        PMID: 26402453     DOI: 10.1016/j.ijcard.2015.09.010

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  8 in total

1.  Plasma Growth Differentiation Factor-15 is a Potential Biomarker for Pediatric Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.

Authors:  Gang Li; Yan Li; Xiao-Qiu Tan; Peng Jia; Jian Zhao; Dong Liu; Ting Wang; Bin Liu
Journal:  Pediatr Cardiol       Date:  2017-08-18       Impact factor: 1.655

2.  Risk Estimates for Atherosclerotic Cardiovascular Disease in Adults With Congenital Heart Disease.

Authors:  George K Lui; Ian S Rogers; Victoria Y Ding; Haley K Hedlin; Kirstie MacMillen; David J Maron; Christy Sillman; Anitra Romfh; Tara C Dade; Christiane Haeffele; Stafford R Grady; Doff B McElhinney; Daniel J Murphy; Susan M Fernandes
Journal:  Am J Cardiol       Date:  2016-09-30       Impact factor: 2.778

Review 3.  Heart Failure Risk Predictions and Prognostic Factors in Adults With Congenital Heart Diseases.

Authors:  Patryk Leczycki; Maciej Banach; Marek Maciejewski; Agata Bielecka-Dabrowa
Journal:  Front Cardiovasc Med       Date:  2022-02-24

Review 4.  Prognostication in Different Heart Failure Phenotypes: The Role of Circulating Biomarkers.

Authors:  Alexander E Berezin
Journal:  J Circ Biomark       Date:  2016-03-16

5.  Exploring the Prognostic Value of Novel Markers in Adults With a Systemic Right Ventricle.

Authors:  Laurie W Geenen; Roderick W J van Grootel; Korhan Akman; Vivan J M Baggen; Myrthe E Menting; Jannet A Eindhoven; Judith A A E Cuypers; Eric Boersma; Annemien E van den Bosch; Jolien W Roos-Hesselink
Journal:  J Am Heart Assoc       Date:  2019-08-21       Impact factor: 5.501

6.  GDF-15 (Growth Differentiation Factor 15) Is Associated With Hospitalization and Mortality in Patients With a Fontan Circulation.

Authors:  Sophie L Meyer; Djoeke Wolff; Floris-Jan S Ridderbos; Graziella Eshuis; Hans Hillege; Tineke P Willems; Tjark Ebels; Joost P van Melle; Rolf M F Berger
Journal:  J Am Heart Assoc       Date:  2020-05-08       Impact factor: 5.501

7.  Associations Between Blood Biomarkers, Cardiac Function, and Adverse Outcome in a Young Fontan Cohort.

Authors:  Eva van den Bosch; Sjoerd S M Bossers; Vivian P Kamphuis; Eric Boersma; Jolien W Roos-Hesselink; Johannes M P J Breur; Arend D J Ten Harkel; Livia Kapusta; Beatrijs Bartelds; Arno A W Roest; Irene M Kuipers; Nico A Blom; Laurens P Koopman; Willem A Helbing
Journal:  J Am Heart Assoc       Date:  2021-02-24       Impact factor: 5.501

8.  Growth differentiation factor-15 combined with N-terminal prohormone of brain natriuretic peptide increase 1-year prognosis prediction value for patients with acute heart failure: a prospective cohort study.

Authors:  Ji Hao; Iokfai Cheang; Li Zhang; Kai Wang; Hui-Min Wang; Qian-Yun Wu; Yan-Li Zhou; Fang Zhou; Dong-Jie Xu; Hai-Feng Zhang; Wen-Ming Yao; Xin-Li Li
Journal:  Chin Med J (Engl)       Date:  2019-10-05       Impact factor: 2.628

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.